SavedAdd your journal

Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2016 / Cilt: 62 - Sayı: 2

Evaluation of the efficacy of pregabalin in oncology patients with neuropathic pain

Nöropatik ağrılı onkoloji hastalarında pregabalinin etkinliğinin değerlendirilmesi

Hakan Levent GÜL
Davut DAMA
Sebahattin ERTEN
Şule KARABULUT GÜL
Nurten İNAN AKSOY
Pages
103–106
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The VAS and LANSS scores were recorded at one and three months among patients receiving pregabalin therapy (300 mg/day).Results: Visual analog scale and LANSS values before the treatment were found 76.83 and 16.70 respectively, 66.16 and 12.83 at the first month, 46.16 and 8.93 at the third month.Conclusion: Our results show that, pregabalin that has been frequently used in recent years for neuropathic pain in the practice of different clinics, was found to be highly effective both in short-term and mid-term in oncology patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the efficacy of pregabalin in oncology patients, which has been frequently used in recent years in the treatment of neuropathic pain.Patients and methods: Between January 2014 and September 2014, 30 oncology patients (17 females, 13 males; mean age 39.9 years; range 28 to 52 years) who were diagnosed with neuropathic pain were included.
📊
Key Findings & Data:Baseline visual analog scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scores were recorded.
💡
Conclusion & Impact:The VAS and LANSS scores were recorded at one and three months among patients receiving pregabalin therapy (300 mg/day).Results: Visual analog scale and LANSS values before the treatment were found 76.83 and 16.70 respectively, 66.16 and 12.83 at the first month, 46.16 and 8.93 at the third month.Conclusion: Our results show that, pregabalin that has been frequently used in recent years for neuropathic pain in the practice of different clinics, was found to be highly effective both in short-term and mid-term in oncology patients
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to evaluate the efficacy of pregabalin in oncology patients, which has been frequently used in recent years in the treatment of neuropathic pain.Patients and methods: Between January 2014 and September 2014, 30 oncology patients (17 females, 13 males; mean age 39.9 years; range 28 to 52 years) who were diagnosed with neuropathic pain were included. Baseline visual analog scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scores were recorded. The VAS and LANSS scores were recorded at one and three months among patients receiving pregabalin therapy (300 mg/day).Results: Visual analog scale and LANSS values before the treatment were found 76.83 and 16.70 respectively, 66.16 and 12.83 at the first month, 46.16 and 8.93 at the third month.Conclusion: Our results show that, pregabalin that has been frequently used in recent years for neuropathic pain in the practice of different clinics, was found to be highly effective both in short-term and mid-term in oncology patients

Özet

Amaç: Bu çalışmada, son yıllarda nöropatik ağrı tedavisinde sıklıkla kullanılmakta olan pregabalinin onkoloji hastalarındaki etkinliği değerlendirildi.Hastalar ve yöntemler: Ocak 2014 - Eylül 2014 tarihleri arasında nöropatik ağrı tanısı konulan 30 onkoloji hastası (17 kadın, 13 erkek; ort. yaş 39.9 yıl; dağılım 28-52 yıl) çalışmaya dahil edildi. Başlangıç görsel analog ölçeği (GAÖ) ve Leeds Nöropatik Bulgu ve Belirtiler Değerlendirme Ölçeği (LANSS) skorları kaydedildi. Pregabalin tedavisi (300 mg/gün) başlanan hastaların birinci ve üçüncü aylarda GAÖ ve LANSS skorları kaydedildi.Bulgular: Görsel analog ölçeği ve LANSS skorları başlangıçta sırasıyla 76.83 ve 16.70, birinci ayda 66.16 ve 12.83 ve üçüncü ayda 46.16 ve 8.93 idi.Sonuç: Çalışma sonuçlarımız, son yıllarda farklı kliniklerin pratiğinde nöropatik ağrı tedavisinde kullanımı giderek artan pregabalinin onkoloji hastalarında hem kısa vadede hem de orta vadede oldukça etkili olduğunu göstermektedir

🔖

Cite This Article

GÜL, H. L., DAMA, D., ERTEN, S., GÜL, Ş. K., AKSOY, N. İ. (2022). Evaluation of the efficacy of pregabalin in oncology patients with neuropathic pain. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 62 - Sayı: 2, 103–106. https://ajindex.com/articles/628652

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Çelebi N, Canbay Ö, Şahin A. Nöropatik ağrıda tanı ve tedavide güncel yaklaşımlar. Turkiye Klinikleri J Med Sci 2007;27:862-9
  2. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21
  3. Davis MP. What is new in neuropathic pain? Support Care Cancer 2007;15:363-72
  4. O᾿Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:22-32
  5. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundam Clin Pharmacol 2007;21:129-36
  6. Suzuki R, Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals 2005;14:175-81
  7. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007;28:220-8
  8. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol 2006;2:95- 106
  9. Berker E. Nöropatik ağrı ve fizyopatolojik mekanizmalar. Türk Fiz Tıp Rehab Derg 2005;51(Özel Ek A):A1-A5
  10. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004;5:427-32
  11. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147-57
  12. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014;5:38-56
  13. Ceyhan M, Tan E. Yeni bir antikonvülsan pregabalin: Preklinik veriler. Türk Nöroloji Dergisi 2008;14;3:161-71
  14. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64
  15. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69
  16. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007;67:1265-89
  17. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-88
  18. İrdesel J. Nöropatik ağrı tedavisi. Turk J Phys Med Rehab 2005;51(Öz